Cormorant Asset Management, LP Sage Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $5.34 Million - $13.7 Million	-88,700 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $1.59 Million - $2.15 Million	-11,300 Reduced 11.3%	88,700 $12.4 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $4.74 Million - $5.49 Million	-30,000 Reduced 23.08%	100,000 $18.3 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $4.8 Million - $8.79 Million	-53,732 Reduced 29.24%	130,000 $20.7 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $513,599 - $875,702	-6,268 Reduced 3.3%	183,732 $17.6 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $6.85 Million - $8.39 Million	-49,619 Reduced 20.71%	190,000 $26.8 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $36.5 Million - $46.1 Million	239,619 New	239,619 $38.6 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.